Ahlskog JE - Search Results

1

Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.

Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Van Gerpen JA, et al. Among authors: ahlskog je. Arch Neurol. 2006 Feb;63(2):205-9. doi: 10.1001/archneur.63.2.205. Arch Neurol. 2006. PMID: 16476808

2

Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide).

Ahlskog JE, Muenter MD, Bailey PA, Stevens PM. Ahlskog JE, et al. Arch Neurol. 1992 May;49(5):560-8. doi: 10.1001/archneur.1992.00530290152026. Arch Neurol. 1992. PMID: 1580821

3

Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.

Ahlskog JE, Muenter MD, Bailey PA, Miller PM. Ahlskog JE, et al. Clin Neuropharmacol. 1991 Jun;14(3):214-27. doi: 10.1097/00002826-199106000-00004. Clin Neuropharmacol. 1991. PMID: 1676932 Clinical Trial.

4

Medical treatment of Parkinson's disease.

Ahlskog JE. Ahlskog JE. Compr Ther. 1989 Mar;15(3):53-9. Compr Ther. 1989. PMID: 2650977 Review. No abstract available.

5

PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.

Muenter MD, Ahlskog JE, Bell G, McManis P. Muenter MD, et al. Among authors: ahlskog je. Neurology. 1988 Oct;38(10):1541-5. doi: 10.1212/wnl.38.10.1541. Neurology. 1988. PMID: 2901697

6

Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.

Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Ahlskog JE, et al. Mayo Clin Proc. 1988 Sep;63(9):876-86. doi: 10.1016/s0025-6196(12)62690-1. Mayo Clin Proc. 1988. PMID: 3045435 Clinical Trial.

7

Pergolide: long-term use in Parkinson's disease.

Ahlskog JE, Muenter MD. Ahlskog JE, et al. Mayo Clin Proc. 1988 Oct;63(10):979-87. doi: 10.1016/s0025-6196(12)64912-x. Mayo Clin Proc. 1988. PMID: 3050301 Clinical Trial.

8

Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.

Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K. Ahlskog JE, et al. Arch Neurol. 1994 Dec;51(12):1236-41. doi: 10.1001/archneur.1994.00540240080020. Arch Neurol. 1994. PMID: 7986180 Clinical Trial.

9

Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.

Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J. Lieberman A, et al. Among authors: ahlskog je. Neurology. 1993 Oct;43(10):1981-4. doi: 10.1212/wnl.43.10.1981. Neurology. 1993. PMID: 8105422 Clinical Trial.

10

Treatment of Parkinson's disease. From theory to practice.

Ahlskog JE. Ahlskog JE. Postgrad Med. 1994 Apr;95(5):52-4, 57-8, 61-4 passim. Postgrad Med. 1994. PMID: 8153048 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters